PTC Therapeutics, Inc. PTCT 深 沪
等待开盘 01-22 09:30:00 美东时间
75.56
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 75.56
- 总市值 60.67亿
- 52周最高 87.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 35.95
- 委 比 0.00%
- 总股本 8028.83万
- 历史最高 87.50
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.03
- 每 手 1
- 风险率 11.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook
PTC Therapeutics ( ($PTCT) ) has issued an announcement. On January 12, 2026, P...
01-13 01:29
PTC Therapeutics projects FY26 product revenue between $700M to $800M
PTC Therapeutics (PTCT) on Monday reported unaudited 2025 product and royalty revenue of ~$823.4 million, exceeding guidance, and unaudited 2025 product revenue of ~$587.8 million. PTC expects to repo...
01-13 00:09
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance ...
01-12 21:30
Royalty Pharma Acquires The Final Portion Of PTC Therapeutics' Remaining Royalty On Roche's Evrysdi For $240M Upfront And Up To $60M In Sales-based Milestones
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and up to $60 million in sales-based
2025-12-30 05:43
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Royalty Pharma has acquired PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, an oral treatment for spinal muscular atrophy, has treated over 21,000 patients globally, with 2024 sales of $1.9 billion and projected to reach $2.9 billion by 2030. Royalty Pharma will now own 100% of the tiered 8% to 16% royalty, with payments increasing based on sales thresholds....
2025-12-29 21:40
Japanese Regulator Approves PTC Therapeutics' Sephience (Sepiapterin) For Phenylketonuria. The Label Includes Individuals Of All Ages And The Full Spectrum Of Disease Severity
PTC will now engage in pricing discussions which are expected to conclude in Q1 2026, with launch occurring shortly thereafter. First Japan product approval for PTC
2025-12-22 20:08
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggre...
2025-12-20 05:30
Cheap smaller cap stocks that promise acceleration in fundamentals – BofA
BofA analysts outlined a list of inexpensive small- and mid-cap stocks with accelerating fundamentals. These are Russell 2000 (IWM) stocks that have cheap valuations along with positive revisions and ...
2025-12-20 00:57
PTC Therapeutics Canada Says Health Canada Approves Sephience For Treatment Of Children And Adults Living With Phenylketonuria
- Broad label includes all age groups and full range of PKU subtypes -TORONTO, Dec. 10, 2025 /CNW/ - PTC Therapeutics Canada ULC announced that Health Canada has approved Sephience™ (sepiapterin) for the
2025-12-10 21:09
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
